Clinical Pharmacy and Practice

Permanent URI for this collection

http://dspace.alquds.edu:4000/handle/20.500.12213/140

Overview

Use of HbA1c to diagnose type 2 diabetes Mellitus. Gestational diabetes and adverse pregnancy outcome is under investigation. Type 2 diabetes in children will be investigated in schools. A platform will be developed to follow up risk factors like obesity, lack of exercise, unhealty food and genetics. The program will highlight the risk factors for each students to be used by parents, Ministry of Education, Ministry of Health and School administration to overcome these risk factors and to treat those who developed diabetes.

Our Team

    • Maher Khdour

    Ph.D.

    • Ahmad Amro

    Ph.D.

    Hussein Hallak

    Ph.D.

    Rania Ghanem

    Ph.D.

    Browse

    Browsing Clinical Pharmacy and Practice by Subject "Jordan"

    Now showing 1 - 1 of 1
    • Thumbnail Image
      Item
      Impact of pharmaceutical care on health outcomes in patients with COPD
      (Springer Science+Business Media B.V. 2011, 2011-11-20) Khdour, Maher; Jarab, Anan; AlQudah, Salam; Shamssain, Mohammed; Mukattash, Tareq
      Background Chronic obstructive pulmonary disease (COPD) treatment goals are often not achieved despite the availability of many effective treatments. Furthermore, clinical pharmacist interventions to improve clinical and humanistic outcomes in COPD patients have not yet been explored and few randomized controlled trials have been reported to evaluate the impact of pharmaceutical care on health outcomes in patients with COPD. Objective The aimof the present studywas to evaluate the impact of pharmaceutical care intervention,with a strong focus on self-management, on a range of clinical and humanistic outcomes in patients with COPD. Setting Outpatient COPD Clinic at the Royal Medical Services Hospital. Method In a randomised, controlled, prospective clinical trial, a total of 133 COPD patients were randomly assigned to intervention or control group. A structured education about COPD and management of its symptoms was delivered by the clinical pharmacist for patients in the intervention group. Patientswere followed up at 6 months during a scheduled visit. Effectiveness of the intervention was assessed in terms of improvement in health-related quality of life,medication adherence, disease knowledge and healthcare utilization. Data collected at baseline and at the 6 month assessment was coded and entered into SPSS software version 17 for statistical analysis. A P value of\0.05 was considered statistically significant. Main outcome measure The primary outcome measure was health-related quality of life improvement. All other data collected including healthcare utilization, COPD knowledge and medication adherence formed secondary outcome measures. Results A total of 66 patients were randomized to the intervention group and 67 patients were randomized to the control group. Although the current study failed to illustrate significant improvement in health-related quality of life parameters, the results indicated significant improvements in COPD knowledge (P\0.001), medication adherence (P\0.05), medication beliefs (P\ 0.01) and significant reduction in hospital admission rates (P\0.05) in intervention patients when compared with control group patients at the end of the study. Conclusion The enhanced patient outcomes as a result of the pharmaceutical care programme in the present study demonstrate the value of an enhanced clinical pharmacy service in achieving the desired health outcomes for patients with COPD.